Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.
Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.
Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.
Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.
Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.
With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.
Arcus Biosciences, Inc. (NYSE:RCUS) has granted options to purchase 31,350 shares and restricted stock units for 15,675 shares to twelve new employees. The options have an exercise price of $21.50, based on the closing price from May 9, 2022. This move is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing innovative cancer therapies and has six investigational medicines in clinical studies targeting various cancer-related pathways.
Arcus Biosciences (RCUS) reported promising results from the third interim analysis of its Phase 2 ARC-7 study for domvanalimab in treating metastatic non-small cell lung cancer (NSCLC). The domvanalimab treatment arms showed significant differentiation in overall response rate (ORR) and duration of response (DoR) compared to zimberelimab alone. The company has $1.3 billion in cash, supporting ongoing Phase 3 trials. Expected updates will continue into late 2022, emphasizing their commitment to advancing innovative cancer therapies.
Arcus Biosciences (NYSE:RCUS) announced it will release its financial results and key pipeline updates for Q1 2022 on May 9, 2022, after U.S. markets close. The company focuses on developing innovative cancer treatments and has advanced six investigational medicines into clinical trials. These include combination therapies targeting TIGIT, PD-1, and the adenosine axis, among others. Founded in 2015, Arcus aims to expedite the development of medicines to improve cancer patient outcomes globally.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to thirteen new employees. A total of 29,050 options were granted at an exercise price of $27.31, based on the closing price on April 25, 2022. Additionally, 14,525 restricted stock units were issued. These equity awards are part of the Company’s 2020 Inducement Plan, approved in January 2020, which allows for stock grants under NYSE rules. Arcus focuses on developing innovative cancer therapies through partnerships and clinical studies.
Arcus Biosciences (NYSE:RCUS) has announced the granting of equity awards to 13 new employees. The awards include options to purchase 28,900 shares at an exercise price of $33.70 per share and restricted stock units for a total of 14,450 shares. This action is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies targeting key biological pathways.
Arcus Biosciences (NYSE:RCUS) announced the granting of equity awards to eleven new employees, totaling options to purchase 30,950 shares at an exercise price of $32.98, the closing price on March 23, 2022. Additionally, restricted stock units were awarded for 15,475 shares. These grants were made under the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus is focused on developing innovative cancer therapies, including six investigational medicines targeting various pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to 14 new employees. A total of 61,000 stock options at an exercise price of $33.03 per share and 30,500 restricted stock units were granted. These awards are part of the company's 2020 Inducement Plan approved by the Board of Directors in January 2020. Founded in 2015, Arcus focuses on developing innovative therapies for cancer treatment, with an emphasis on combination approaches targeting various biological pathways.
Arcus Biosciences (NYSE:RCUS) announced promising initial data for AB521, a HIF-2a inhibitor, suggesting it may outperform the only approved HIF-2a inhibitor. The findings were detailed at the ESMO Targeted Anticancer Therapies Congress on March 7-8, 2022. Future presentations will include PK/PD modeling for etrumadenant, quemliclustat, and zimberelimab at the ASCPT conference on March 16-18, 2022, and insights into enhancing anti-tumor immunity at AACR on April 8-13, 2022. The company is progressing with its clinical trials, particularly a Phase 1/1b study for AB521 in renal cancer.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of equity awards to seven new employees, totaling 20,450 stock options at an exercise price of $30.01 per share, based on the February 23, 2022 closing price. Additionally, 10,225 restricted stock units were awarded. The grants fall under the 2020 Inducement Plan approved by the Board of Directors in January 2020, complying with NYSE regulations.
Arcus is committed to developing innovative cancer therapies and has advanced multiple investigational medicines into clinical studies.
Arcus Biosciences reported strong financial results for the fourth quarter and full year 2021, highlighting a net income of $279.4 million for Q4 compared to a net loss of $51.9 million in the previous year. Revenues surged to $354.5 million, significantly up from $9.5 million year-over-year, mainly due to Gilead's collaboration. The company holds approximately $1.4 billion in cash, ensuring funding into 2026. Arcus has multiple Phase 3 studies underway for its lead drug, domvanalimab, in various cancers, indicating robust pipeline growth.
FAQ
What is the current stock price of Arcus Biosciences (RCUS)?
What is the market cap of Arcus Biosciences (RCUS)?
What does Arcus Biosciences, Inc. do?
Where is Arcus Biosciences located?
When was Arcus Biosciences founded?
What is the core focus of Arcus Biosciences' research?
What are some of Arcus Biosciences' main products?
What types of cancer does Arcus Biosciences target?
Does Arcus Biosciences outsource its research and development?
With whom does Arcus Biosciences have significant partnerships?
What makes Arcus Biosciences unique?